Open AccessWhat Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?
Author(s) -
Salih Tokmak,
Yüksel Gümürdülü,
Didem Arslan,
İbrahim O Kara,
Ahmet Barış Güzel
Publication year - 2021
Publication title -
the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2021.201131
Subject(s) - medicine , rituximab , antibody , hepatitis b virus , group b , gastroenterology , hepatitis b , prospective cohort study , immunology , virus
Reactivation of Hepatitis B (HBVr) related to immunosuppressive drug therapy (ISDT) in patients with resolved and past infection is a challenging entity. The number of prospective long-term studies is limited.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom